Bevacizumab + INCA33890 for Colorectal Cancer

This trial tests a new combination of treatments to determine if it outperforms the standard approach for individuals with previously untreated metastatic colorectal cancer. The trial adds a new drug, INCA33890 (an experimental treatment), to the usual chemotherapy and bevacizumab (a targeted therapy) to assess improvement in results. Participants will receive either this new combination or a placebo with the standard treatment. Suitable candidates have stage IV colorectal cancer that cannot be surgically removed and have not yet undergone chemotherapy for their metastatic disease. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to potentially groundbreaking treatment advancements.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that INCA33890 has been studied for its effects and safety. In one study, 105 patients received only INCA33890, and about 15% experienced a partial response, meaning their cancer shrank somewhat. However, the study did not provide specific details about safety or side effects.

Bevacizumab is a well-known treatment often used for various cancers. The FDA has approved it for treating some cancers, indicating it is generally safe when used correctly. Bevacizumab can have side effects, but these are usually known and managed in clinical settings.

Unlike the standard treatment for colorectal cancer, which typically includes chemotherapy regimens like FOLFOX, the investigational drug INCA33890 works differently by being combined with bevacizumab, an antibody that targets blood vessel growth in tumors. Researchers are excited about INCA33890 because it may enhance the effectiveness of bevacizumab and FOLFOX by adding a novel mechanism that targets specific pathways in cancer cells, potentially leading to improved outcomes. This unique combination could offer a more powerful approach against tumors, addressing the tough-to-treat aspects of colorectal cancer.

Research shows that bevacizumab, when combined with standard chemotherapy like FOLFOX, can slow colorectal cancer growth by cutting off the blood supply tumors need. In this trial, one group of participants will receive INCA33890 alongside bevacizumab and FOLFOX. Studies have found that INCA33890, a new drug, targets specific proteins that aid tumor growth. In earlier research, 15.2% of patients who took INCA33890 alone experienced tumor shrinkage. Although specific data on using INCA33890 with bevacizumab for colorectal cancer is not yet available, its mechanism suggests potential benefits. This combination aims to enhance the effects of chemotherapy and bevacizumab, potentially offering a new treatment option.¹²³⁶⁷